Gondolabio
3 known investors
GondolaBio is a clinical-stage biopharmaceutical company developing therapeutics for patients with genetic diseases, with a lead oral small-molecule program (PORT-77) targeting erythropoietic protoporphyria and X-linked protoporphyria. A sister company of BridgeBio Pharma launched in 2024, it runs a decentralized drug-development model with a pipeline spanning multiple rare genetic conditions.
BiotechHealthtech
Investors · 3
Frequently asked questions
- What does Gondolabio do?
- GondolaBio is a clinical-stage biopharmaceutical company developing therapeutics for patients with genetic diseases, with a lead oral small-molecule program (PORT-77) targeting erythropoietic protoporphyria and X-linked protoporphyria. A sister company of BridgeBio Pharma launched in 2024, it runs a decentralized drug-development model with a pipeline spanning multiple rare genetic conditions.
- Who are Gondolabio's investors?
- Gondolabio's investors include Aisling Capital, Frazier Life Sciences, Patient Square Capital.